Hematopoietic stem cell transplantation (HSCT) for primary systemic vasculitis and related diseases

References

• Burt RK, Marmont A, Oyama Y, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: The evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006; 54(12)3750–3760
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2)187–192
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82(1)60–76
   PubMed Web of Science ®Google Scholar
• Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behcet's disease. J Rheumatol 1992; 19(3)402–410
   PubMedGoogle Scholar
• Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behcet's syndrome: A report of 24 cases. Br J Rheumatol 1994; 33(1)48–51
   PubMedGoogle Scholar
• Tillie-Leblond I, Wallaert B, Leblond D, et al. Respiratory involvement in relapsing polychondritis. Clinical, functional, endoscopic, and radiographic evaluations. Medicine (Baltimore) 1998; 77(3)168–176
   PubMedGoogle Scholar
• Barretto SN, Oliveira GH, Michet CJ, Jr., et al. Multiple cardiovascular complications in a patient with relapsing polychondritis. Mayo Clin Proc 2002; 77(9)971–974
   PubMedGoogle Scholar
• Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44(3)666–675
   PubMed Web of Science ®Google Scholar
• Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients. Arthritis Rheum 2000; 43(5)1021–1032
   PubMedGoogle Scholar
• Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996; 101(2)129–134
   PubMedGoogle Scholar
• Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124(5)477–484
   PubMed Web of Science ®Google Scholar
• Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257(6)540–548
   PubMedGoogle Scholar
• Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52(1)262–268
   PubMedGoogle Scholar
• Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101(10)3827–3834
   PubMed Web of Science ®Google Scholar
• Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65(7)853–858
   PubMed Web of Science ®Google Scholar
• Cohen H, Green S, Jones S, et al. Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia. Rheumatology (Oxford) 2007; 46(2)366–367
   PubMedGoogle Scholar
• Benenson E, Fries JW, Heilig B, et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005; 24(3)251–257
   PubMedGoogle Scholar
• Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54(5)1608–1618
   PubMedGoogle Scholar
• Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87(4)423–431
   PubMed Web of Science ®Google Scholar
• Daikeler T, Kotter I, Bocelli Tyndall C, et al. Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: A retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann Rheum Dis 2007; 66(2)202–207
   PubMedGoogle Scholar
• Tomonari A, Tojo A, Takahashi T, et al. Resolution of Behcet's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome. Ann Hematol 2004; 83(7)464–466
   PubMedGoogle Scholar
• Wedderburn LR, Jeffery R, White H, et al. Autologous stem cell transplantation for paediatric-onset polyarteritis nodosa: Changes in autoimmune phenotype in the context of reduced diversity of the T- and B-cell repertoires, and evidence for reversion from the CD45RO(+) to RA(+) phenotype. Rheumatology (Oxford) 2001; 40(11)1299–1307
   PubMedGoogle Scholar
• Marmont AM, Gualandi F, Piaggio G, et al. Allogeneic bone marrow transplantation (BMT) for refractory Behcet's disease with severe CNS involvement. Bone Marrow Transplant 2006; 37(11)1061–1063
   PubMed Web of Science ®Google Scholar
• Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87(11)671–678
   PubMed Web of Science ®Google Scholar
• Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40(2)371–380
   PubMed Web of Science ®Google Scholar
• Fiehn C, Hensel M. High dose chemotherapy with hematopoietic stem cell transplantation in primary systemic vasculitis, Behcet's disease and Sjögren's syndrome. Stem cell therapy for autoimmune disease, RK Burt, A Marmont. Landes Bioscience, Georgetown, TX 2004; 411–418
   Google Scholar
• Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001; 60(7)702–707
   PubMedGoogle Scholar
• Maurer B, Hensel M, Max R, et al. Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: Analysis after 5 years of follow up. Ann Rheum Dis 2006; 65(1)127–129
   PubMedGoogle Scholar
• Hensel M, Breitbart A, Ho AD. Autologous hematopoietic stem-cell transplantation for Behcet's disease with pulmonary involvement. N Engl J Med 2001; 344(1)69
   PubMedGoogle Scholar
• Rossi G, Moretta A, Locatelli F. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood 2004; 103(2)748–750
   PubMedGoogle Scholar
• Daikeler T, Erley C, Mohren M, et al. Fever and increasing cANCA titre after kidney and autologous stem cell transplantation for Wegener's granulomatosis. Ann Rheum Dis 2005; 64(4)646–647
   PubMedGoogle Scholar
• Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I–II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65(4)508–514
   PubMedGoogle Scholar
• Voltarelli JC, Oliveira MC, Stracieri AB, et al. Haematopoietic stem cell transplantation for refractory Takayasu's arteritis. Rheumatology (Oxford) 2004; 43(10)1308–1309
   PubMedGoogle Scholar
• Jones OY, Good RA, Cahill RA. Nonmyeloablative allogeneic bone marrow transplantation for treatment of childhood overlap syndrome and small vessel vasculitis. Bone Marrow Transplant 2004; 33(10)1061–1063
   PubMedGoogle Scholar